Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Healthy
Interventions
DRUG

Darifenacin

Darifenacin tablets 15 mg once daily

DRUG

Tolterodine

Tolterodine extended release (ER) 4 mg once daily

DRUG

Placebo

Placebo tablet once daily

Trial Locations (21)

Unknown

Investigative Site, Phoenix

Investigative Site, Tempe

Investigative Site, Little Rock

Investigative Site, San Diego

Investigative Site, Washington D.C.

Investigative Site, Fort Myers

Investigative Site, Jacksonville

Investigative Site, Jupiter

Investigative Site, Miami

Investigative Site, Orlando

Investigative Site, Overland Park

Investigative Site, Topeka

Investigative Site, Riverdale

Investigative Site, Wellesley Hills

Investigative Site, Springfield

Investigative Site, Hackensack

Investigative Site, Burlington

Investigative Site, Greensboro

Investigative Site, Oklahoma City

Investigative Site, Knoxville

Investigative Site, Morgantown

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Procter and Gamble

INDUSTRY

lead

Novartis

INDUSTRY